Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. (14th July 2017)

• Record Type: Journal Article
• Authors: Cohen, E. E. W.; Licitra, L. F.; Burtness, B.; Fayette, J.; Gauler, T.; Clement, P. M.; Grau, J. J.; del Campo, J. M.; Mailliez, A.; Haddad, R. I.; Vermorken, J. B.; Tahara, M.; Guigay, J.; Geoffrois, L.; Merlano, M. C.; Dupuis, N.; Krämer, N.; Cong, X. J.; Gibson, N.; Solca, F.; Ehrnrooth, E.; Machiels, J.-P. H.
• Is Part Of: Annals of oncology. Volume 28:Number 10(2017)
• Page Start: 2526
• Page End: 2532
• Publication Date: 2017-07-14
• Subjects: afatinib -- methotrexate -- HNSCC -- biomarker -- phase III -- EGFR; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdx344
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Here, we evaluated association of prespecified biomarkers with efficacy outcomes in LUX-H&N1. Patients and methods: Randomized patients with R/M HNSCC and progression following ≥2 cycles of platinum therapy received afatinib (40 mg/day) or methotrexate (40 mg/m 2 /week). Tumor/serum samples were collected at study entry for patients who volunteered for inclusion in biomarker analyses. Tumor biomarkers, including p16 (prespecified subgroup; all tumor subsites), EGFR, HER2, HER3, c-MET and PTEN, were assessed using tissue microarray cores and slides; serum protein was evaluated using the VeriStrat ® test. Biomarkers were correlated with efficacy outcomes. Results: Of 483 randomized patients, 326 (67%) were included in the biomarker analyses; baseline characteristics were consistent with the overall study population. Median PFS favored afatinib over methotrexate in patients with p16-negative [2.7 versus 1.6 months; HR 0.70 (95% CI 0.50–0.97)], EGFR -amplified [2.8 versus 1.5 months; HR 0.53 (0.33–0.85)], HER3-low [2.8 versus 1.8 months; HR 0.57 (0.37–0.88)], and PTEN-high [1.6 versus 1.4 months; HR 0.55 (0.29–1.05)] tumors. Afatinib also improved PFS in combined subsets of patients with p16-negative and EGFR -amplified tumors [2.7 versus 1.5 months; HR 0.47 (0.28–0.80)], and patients with p16-negative tumors who were EGFR therapy-naïve [4.0 versus 2.4 months; HR 0.55 (0.31–0.98)]. PFS was improved in afatinib-treated patients who were VeriStrat 'Good' versus 'Poor' [2.7 versus 1.5 months; HR 0.71 (0.49–0.94)], but no treatment interaction was observed. Afatinib improved tumor response versus methotrexate in all subsets analyzed except for those with p16-positive disease ( n = 35). Conclusions: Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR -amplified, HER3-low, PTEN-high). Future studies are warranted to validate these findings. Clinical trial registration: NCT01345682.